B細胞非ホジキンリンパ腫治療のストラデジ

出版社: 先端医学社
著者:
発行日: 2003-06-10
分野: 臨床医学:一般  >  癌/腫瘍一般
ISBN: 4884071026
電子書籍版: 2003-06-10 (第1版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

4,730 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,365 円(税込)

商品紹介

本書は、B細胞リンパ腫に対する最新の治療の動向と将来の可能性について第一線の専門家からの解説書である。 

目次

  • B細胞非ホジキンリンパ腫治療のストラデジ

    ―目次―

    1.Aggressive non-Hodgkin’s lymphoma
     Prt1: び慢性大細胞型リンパ種の治療
     Prt2: マントル細胞リンパ種の治療

    2.Indolent B-cell non-Hodgkin’s lymphoma
     Prt1: 濾胞性リンパ種の治療
     Prt2: Marginal zone Bリンパ腫、とくにMALTリンパ腫の治療

    3.Highly aggressive B-cell non-Hodgkin’s lymphoma
     1現在のスタンダード治療とその成績
     2造血幹細胞移植併用大量化学療法
     3第二/第三世代化学療法
     4CODOX-M/IVAC療法

    4.B細胞非ホジキンリンパ腫に対する新たな分子標的治療
     1モノクローナル抗体治療
     2新たな分子標的治療

    5.遺伝子診断 〜腫瘍の発症機序の研究から実際の治療への応用
     1病理の特徴をつかむための様々な検出法
     2表面マーカー、染色体、遺伝子診断の意義

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[1] Aggressive non-Hodgkin's lymphoma

P.5 掲載の参考文献
1) World Health Organization Classification Tumours:Tumours of Haematopoietic and Lymphoid Tissues. Ed by Jaffe ES, Harris NL, Stein H, Vardiman, IARC Press, 2001
2) Goldie JH & Coldman AJ:A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733, 1979
3) Klimo P et al:MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102:596-602, 1985
6) Dana BW et al:m-BACOD treatment for intermediate-and high-grade malignant lymphomas:a Southwest Oncology Group Phase II trial. J Clin Oncol 8:1155-1162, 1990
7) Miller TP et al:Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE CytaBOM:A group wide Southwest Oncology Group study. J Clin Oncol 8:1951-1958, 1990
8) De Vita VT et al:The chemotherapy of lymphomas:looking back, moving forward-the Richard and Hinda Rosenthal foundation award lecture. Cancer Res 47:5810-5824, 1987
10) Fisher RI:Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 40 suppl:S42-S46, 1997
13) Wolf M et al:Long-term survival advantage of MACOP-B over CHOP in intermediate garadenon-Hodgkin's lymphoma. The Australian and New Zealand lymphoma group. Ann Oncol 8:71-75, 1997
14) Linch DC et al:A randomized comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma-a British National Lymphoma Investigation report. Br J Cancer 74:318-322, 1996
15) Montserrat E et al:CHOP vs ProMACE-CytaBOM in the treatment of aggressive non Hodgkin lymphoma:long-term results of malticenter randomized trial. (PETHEMA;Spanish cooperative Group for the study of hematologic malignancies treatment. Spanish Society of Hematology. Eur J Haematol 57:377-383, 1996
16) Jerkeman M et al:CHOP versus MACOP-B in aggressive lymphoma-a Nordic Lymphoma Group randomized trial. Ann Oncol 10:1079-1086, 1999
17) Messori A et al:Survival in patients with intermediate or high grade non-Hodgkin's lymphoma:meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 84:303-307, 2001
19) Miller TP et al:CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphoma:update of the Southwest Oncology Group (SWOG) randomized trial. Proc Am Soc Hematol #3024, 2001
20) Horning SJ et al:Final report of E 1484:CHOP v CHOP+radiotherapy for limited stage diffuse aggressive lymphoma. Proc Am Soc Hematol #3023, 2001
21) Shipp MA et al:A predictive model for aggressive NHL:The International Non-Hodgkin's Lymphoma Prognostic Factor Project. N Engl J Med 329:987-997, 1993
P.11 掲載の参考文献
1) Takagi T et al:Stage I malignant lymphoma of Waldeyer's ring:frequent relapse after radiation therapy. Ann Oncol 3:137-139, 1992
2) Kaminski MS et al:Factors predicting survival in adults with stage I and II large cell lymphoma treated with primary radiation therapy. Ann Intern Med 104:747-756, 1986
5) Tondini C et al:Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas. J Clin Oncol 11:720-725, 1993
6) Glick JH et al:An ECOG randomized phase III trial of CHOP vs. CHOP+radiotherapy (XRT) for intermediate grade early stage non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 14:391, 1995
8) Cabanillas F et al:Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types. Cancer 46:2356-2359, 1980
9) Miller T et al:Initial chemotherapy for clinically localized lymphomas unfavorable histology. Blood 62:413-418, 1983
10) Connors J et al:Brief chemotherapy and involved field radiation therapy for limited-stage histologically aggressive lymphoma. Ann Intern Med 107:25-30, 1987
12) Miller T et al:CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas:update of the Southwest Oncology Group (SWOG) randomized trial. Blood 97:3024, 2001
P.18 掲載の参考文献
1) DeVita VT Jr et al:Advanced diffuse histiocytic lymphoma, a potentially curable diseases:Results with combination chemotherapy. Lancet I:248-250, 1975
2) Jones SE et al:Superiority of Adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma:a Southwest Oncology Group study. Cancer 43:417-425, 1979
3) Skarin AT et al:Combination chemotherapy of advanced non-Hodgkin's lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP). Blood 49:759-770, 1977
4) Sweet DL et al:Cyclophosphamide, vincristine, methotrexate with leucovorin rescuer, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Ann Intern Med 92:785-790, 1980
5) Goldie JH et al:A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733, 1979
7) Shipp MA et al:The m-BACOD combination chemotherapy regimen in large-cell lymphoma:Analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol 8:84-93, 1990
8) Fisher RI et al:Diffuse aggressive lymphomas:Increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 98:304-309, 1983
9) Klimo P et al:MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102:596-602, 1985
10) Coleman M et al:The COP-BLAM programs:evolving chemotherapy concepts in large cell lymphoma. Semin Hematol 25 (Suppl.2):23-33, 1988
11) Longo DL et al:Superiority of ProMACE CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma:results of a prospective randomized trial. J Clin Oncol 9:25-38, 1991
13) Armitage JO et al:Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, Adriamycin, vincristine, and prednisone (CHOP) . Cancer 50:1695-1702, 1982
16) Dana BW et al:m-BACOD treatment for intermediate-and high-grade malignant lymphomas:A Southwest Oncology Group phase II trial J Clin Oncol 8:1155-1162, 1990
17) Weick JK et al:Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B:a Southwest Oncology Group study. J Clin Oncol 9:748-753, 1991
18) Schneider AM et al:Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate-and some high-grade non-Hodgkin's lymphomas. J Clin Oncol 8:94-102, 1990
19) Miller TP et al:Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE CytaBOM:A groupwide Southwest Oncology Group study. J Clin Oncol 8:1951-1958, 1990
22) Montserrat E et al:CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas:long-term results of a multicenter randomized trial. Eur J Haematol 57:377-383, 1996
23) Jerkeman M et al:CHOP versus MACOP-B in aggressive lymphoma-a Nordic Lymphoma Group randomized trial. Ann Oncol 10:1079-1086, 1999
24) Wolf M et al:Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. Ann Oncol 8 (Suppl.1):S71-S75, 1997
26) Shipp MA:Prognostic factors in aggressive non-Hodgkin's lymphoma:who has"high-risk"disease?. Blood 83:1165-1173, 1994
27) Armitage JO et al:New approach to classifying non-Hodgkin's lymphomas:clinical features of the major hisologic subtypes. J Clin Oncol 16:2780-2795, 1998
29) Haioun C et al:Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma:updated results of the prospective study LNH 87-2. J Clin Oncol 15:1131-1137, 1997
30) Gianni AM et al:High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290-1297, 1997
31) Santini G et al:VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma:results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative study group. J Clin Oncol 16:2796-2802, 1998
32) Shipp MA et al:International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphoma:report of the Jury. J Clin Oncol 17:423-429, 1999
37) Velasquez WS et al:Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin-vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone;application of prognostic models to data analysis. Cancer 73:2408-2416, 1994
P.24 掲載の参考文献
2) Messori A et al:Survival in patients with intermediate or high grade non-Hodgkin's lymphoma:meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 84:303-307, 2001
3) Wolf M et al:Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. Ann Oncol 8:S71-S75, 1997
5) DeVita VTJr et al:Advanced diffuse histiocytic lymphoma:a potentially curative disease. Lancet I:248-250, 1975
10) Shipp MA et al:International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas:Report of the Jury. J Clin Oncol 17:423-429, 1999
11) Haioun C et al:Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma:Final analysis of the prospective LNH 87-2 protocol-A Groupe d'Etude des Lymphomes de l' Adulte study. J Clin Oncol 18:3025-3030, 2000
13) Santoro A et al:Dose-escalation of CHOP in non-Hodgkin's lymphoma. Ann Oncol 10:519-525, 1999
14) Itoh K et al:Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma. Ann Oncol 11:1241-1247, 2000
15) Tanosaki R et al:Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma. Cancer 74:1939-1944, 1994
16) Pronzato P et al:High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non-Hodgkin's lymphoma:a phase II study. Br J Cancer 78:777-780, 1998
17) Balzarotti M et al:Intensified CHOP regimen in aggressive lymphomas:maximal dose intensity and dose density of doxorubicin and cyclophosphamide. Ann Oncol 13:1341-1346, 2002
18) Itoh K et al:Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma:Japan Clinical Oncology Group study 9505. Ann Oncol 13:1347-1355, 2002
19) Itoh K et al:Randomized comparison of mobilization kinetics of circulating CD 34+ cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 38:521-532, 2000
20) Freedman A et al:Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation. Blood 90:4996-5001, 1997
21) Pfreundschuh M et al:2-weekly CHOP (CHOP-14):the new standard regimen for patients with aggressive non-Hodgkin's lymphoma (NHL) >60 years of age. Ann Oncol 13 (suppl. 2):27, 2002
P.34 掲載の参考文献
1) Tedder TF et al:CD20:a regulator of cell-cycle progression of Blymphocytes. Immunol Today 15:450-454, 1994
2) Pulczynski S et al:Modulation and intracellular transport of CD20 and CD 21 antigens induced by B1 and B2 monoclonal antibodies in Raji and Jok-1 cells-an immunofluorescence and immunoelectron microscopy study. Leuk Res 18:541-52, 1994
3) Polyak MJ et al:Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes;heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 99:3256-3262, 2002
4) Reff ME et al:Depletion of B Cells In Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD20. Blood 83:435-445, 1994
5) Tobinai K et al:Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C 2 B 8, rituximab) in relapsed B-cell lymphoma. The IDEC-C 2 B 8 Study Group. Ann Oncol 9:527-534, 1998
7) Golay J et al:Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro:CD55 and CD59 regulate complement mediated cell lysis. Blood 95:3900-3908, 2000
9) Golay J et al:CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia:further regulation by CD55 and CD59. Blood 98:3383-3389, 2001
10) Bellosillo B et al:Complement-mediated cell death induced by rituximab in B-cell lympho-proliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 98:2771-2777, 2001
11) Weng WK et al:Expression of complement inhibitors CD46, CD55, and CD590n tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 98:1352-1357, 2001
12) Clynes RA et al:Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443-446, 2000
13) Cartron G et al:Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758, 2002
14) Manches O et al:In vitro mechanisms of action of rituximab on primary non-Hodgkin's lymphomas. Blood 101:949-954, 2003
15) Deans Jp et al:Association of tyrosine and serine kinases with the B cell surface antigen CD20. J Immunol 151:4494-4504, 1993
16) Tedder TF et al:The B cell surface molecule B lis functionally linked with B cell activation and differentiation. J Immunol 135:973-979, 1985
17) Tedder TE et al:Antibodies reactive with the Bl molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur J Immunol 16:881-887, 1986
18) Golay JT et al:The CD20 (bp 35) antigen is involved in activation of B cells from the G 0 to the G1 phase of the cell cycle. J Immunol 135:3795-3801, 1985
19) Taji H et al:Growth inhibition of CD20-positive Blymphoma cell lines by IDEC-C 2 B 8 anti-CD20 monoclonal antibody. Jpn J Cancer Res 89:748, 1998
20) Maloney DG et al:The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines. Blood 88:637 a (Abstract), 1996
21) Shan D et al:Apoptosis of malignant human B cell by ligation of CD20 with monoclonal antibodies. Blood 91:1644-1652, 1998
22) Shan D et al:Signaling events involved in anti CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48:673-683, 2000
24) Mathas S et al:Anti-CD20-and B-cell receptor-mediated apoptosis:evidence for shared intracellular signaling pathways. Cancer Res 60:7170-7176, 2000
26) Demidem A et al:Chimeric anti-CD20 (IDEC-C 2 B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12:177-186, 1997
27) Di Gaetano N et al:Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 114:800-809, 2001
28) Rose AL et al:Glucocorticoids and rituximab in vitro:synergistic direct antiproliferative and apoptotic effects. Blood 100:1765-1773, 2002
29) Alas S et al:Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7:709-723, 2001
30) Alas S et al:Rituximab inactivates signal transducer and activation of transcription 3 (STAT 3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61:5137-5144, 2001
31) Chow KU et al:Anti-CD20 antibody (IDEC-C 2 B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro:role of cytokines, complement, and caspases. Haematologica 87:33-43, 2002
P.39 掲載の参考文献
1) Coiffier B:What treatment for elderly patients with aggressive lymphoma? Ann Oncol 5:863-875, 1994
2) Meyer RM et al:Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. A. J Clin Oncol 13:2386-2393, 1995
3) Coiffier B et al:Rituximab (anti-CD20 mono-clonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma:The LNH 93-5 study. Blood 92:1927-1932, 1998
4) Pan D el al:Clinical outcomes of patients treated with rituximab for relapsed or refractory aggressive non-Hodgkin's lymphoma in the post transplant setting. Blood 96:405 a, 2000
5) Coiffier B:Rituximab in the treatment of diffuse large B-cell lymphomas. Semin Oncol 29 (Suppl.2):30-35, 2002
7) Van Der Kolk LE et al:Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100:2257-2259, 2002
9) Rubenstein JL et al:Rituximab therapy for CNS lymphomas:targeting the leptomeningeal compartment. Blood, 2002 Sep 5 [epub ahead of print]
10) Pels H et al:Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J Neurooncol 59:211-216, 2002
11) Harjunpaa A et al:Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma 42:711-718, 2001
12) Hallel M et al:Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement. Onkologie 24:491-494, 2001
P.46 掲載の参考文献
2) 木下朝博ほか:キメラ型抗CD20抗体. 低悪性度Bリンパ腫治療の新しいモダリティ. 血液・腫瘍科 42:231-238, 2001
3) Demidem A et al:Chimeric anti-CD20 (IDEC-C 2 B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12:177-186, 1997
4) Coiffier B et al:Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma:a multicenter phase II study. Blood 92:1927-1932, 1998
5) Igarashi T et al:Phase II and pharmacokinetic study of rituximab with eight weekly infusions in relapsed aggressive B-cell non-Hodgkin's lymphoma (B-NHL). Proc Am Soc Clin Oncol 286 a (abstract no 1142), 2002
7) Czuczman MS et al:Progression Free Survival (PFS) after Six Years (Median) Follow-Up of the First Clinical Trial of Rituximab/CHOP Chemoimmunotherapy. Blood 98:601 a, 2001
8) Vose J et al:Phase II Study of Rituximab in Combination with CHOP Chemotherapy in Patients with Previously Untreated, Aggressive Non-Hodgkin's Lymphoma. J Clin Oncol 19:389-397, 2001
11) Coiffier B et al:Rituximab plus CHOP for Diffuse Large-B-Cell Lymphoma-The authors reply. N Engl J Med 346:1831, 2002
12) Pfreundschuh M et al:2-weekly CHOP (CHOP-14):The new standard regimen for patients with aggressive non-Hodgkin's lymphoma (NHL) >60 years of age. Annual Oncol 13 (Suppl.2):27, 2002
P.54 掲載の参考文献
1) Wilson WH et al:EPOCH chemotherapy:Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 11:1573-1582, 1993
2) Gutierrez M et al:Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas:an 8-years follow-up study of EPOCH. J Clin Oncol 18:3633-3642, 2000
3) Wilson WH et al:Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas:a pharmacodynamic approach with high efficacy. Blood 99:2685-2693, 2002
4) Wilson WH et al:The role of rituximab and chemotherapy in aggressive B-cell lymphoma:A preliminary report of dose-adjusted EPOCH-R. Semin Oncol 29:41-47, 2002
5) Goldstein L et al:Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116-124, 1989
7) Wilson WH et al:Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 89:601-609, 1997
10) Deans JP et al:Association of tyrosine and serine kinase with the B cell surface antigen CD20. Induction via CD20 0f tyrosine phosphorylation and ctivation of phospholipase C-gamma 2. J Immunol 151:4494-4504, 1993
11) Wilson WH:Chemotherapy sensitization by rituximab:experimental and clinical evidence. Sem Oncol 27:30-36, 2000
12) Wilson WH et al:Rituximab may overcome bcl-2-associated chemotherapy resistance in untreated diffuse large B-cell lymphomas. Blood 98:343 a, 2001
13) 福田治彦, 西條長宏:NCI-CTC日本語訳JCOG版-第2版について-. 癌と化学療法 28:1993-2027, 2001
14) 土橋史明, 薄井紀子ほか:再発・治療抵抗性リンパ系腫瘍に対するEPOCH療法の試み. 臨床血液 39:267-272, 1998
15) Jost LM et al:Rituximab-EPOCH-an effective salvage regimens for relapsed, refractory, or transformed B-cell lymphoma. Results of a phase II study. Proc Am Soc Clin Oncol 20:290 a, 2001
16) Coiffier MG et al:Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing and refractory aggressive lymphoma:A multicenter phase II study. Blood 92:1927-1932, 1998
P.55 掲載の参考文献
P.60 掲載の参考文献
1) Philip T et al:Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses pf chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
2) Haioun C et al:Benefit of autologous bone marrow transplantation (ABMT) over sequential chemotherapy in poor risk aggressive non-Hodgkin's lymphoma (NHL) . J Clin Oncol 15:1131-1137, 1997
3) Santini G et al:VACOP-B vs VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma:Results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 16:2796-2802, 1998
4) Gianni AM et al:High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290-1297, 1997
5) Coiffer B el al:CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
6) Press OW et al:A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophoaphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96:2934-2942, 2000
7) Khouri IF et al:Nonablative allogenic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma:low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98:3595-3599, 2001
8) Hammert LC et al:Purging marrow or peripheral blood stem cells for autografting. Curr Opinion hematol 4:423-428, 1997
10) Magni M et al:Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell lymphoma:evidence for a role of both chemotherapy and rituximab infusion. Blood 96:864-869, 2000
11) Voso MT et al:In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 109:729-735, 2000
12) Moos M et al:The remission status before and the PCR status after high dose therapy with peripheral blood stem cell support are prognostic factors for relapse free survival in patients with follicular non-Hodgkin's lymphoma. Leukemia 12:1971-1976, 1998
13) Sharp JG et al:Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by a culture technique. Blood 79:1074-1080, 1992
15) Jacquy C et al:A quantitative study of peripheral blood stem cell contamination ill diffuse large-cell non-Hodgkin's lymphoma:one-half of patients significantly mobilize malignant cells. Br J Haematol 110:631-637, 2000
16) Flohr T et al:Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrou, Transplant 29:769-775, 2002
17) Deisseroth AB et al:Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogeneous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 83:3068-3076, 1994
18) Brenner MK et al:Genemarking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341:85-86, 1993
19) Andersen NS et al:Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 90:4212-4221, 1997
21) Gribben JG et al:Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81:3449-3457, 1993
25) Horwitz SM et al:Adjuvant rituximab after autologous peripheral blood stem cell transplant (APBSCT) results in delayed immune reconstitution without increase in infectious complications. Blood 96 (Suppl.1):384 a (Abstr. 1657), 2000
26) Ragnhammar P et al:Cytotoxicity of white blood cells activated by granulocyte-colony stimulating factor, granulocyte/macrophage-colony stimulating factor against tumor cells in the presence of various monoclonal antibodies. Cancer Immunol Immunother 39:254-262, 1994
27) Nagler A et al:Granulocyte-macrophage colony stimulating factor dependent monocyte-mediated cytotoxicity post-autologous bone marrow transplantation. Leuk Res 20:637-643, 1996
28) Lazzarino M et al:A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 116:229-235, 2002
29) Ladetto M et al:Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia 15:1941-1949, 2001
P.67 掲載の参考文献
2) The International Non-Hodgkin's Lymphoma Prognostic Factors Project:A prospective model for advanced non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
4) Anderson KC et al:Expression of human B cell-associated antigens on leukemias and lymphomas:A model of human B cell differentiation. Blood 63:1424-1433, 1984
5) Reff ME et al:Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445, 1994
6) Shan D et al:Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48:673-683, 2000
8) McLaughlin P et al:Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
9) Coiffier B et al:Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma:A multicenter phase II study. Blood 92:1927-1932, 1998
10) Foran JM et al:Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody):Analysis of factors associated with response. Ann Oncol 11 (suppl. 1):117-121, 2000
11) Alas S et al:Rituximab Inactivates Signal Transducer and Activation of Transcription 3 (STAT 3) Activity in B-Non-Hodgkin's Lymphoma through Inhibition of the Interleukin 10 Autocrine/Paracrine Loop and Results in Down-Regulation of Bcl-2 and Sensitization to Cytotoxic Drugs. Cancer Research 61:5137-5144, 2001
12) Vose JM et al:Phase II Study of Rituximab in Combination with CHOP Chemotherapy in Patients with Previously Untreated, Aggressive Non-Hodgkin's Lymphoma. J Clini Oncol 19:389-397, 2001
14) Schmits R et al:Therapeutic strategies for aggressive lymphomas:the trials of the DSHNHL. Ann Hematol 80 (Suppl.3):B77-83, 2001
15) Gianni AM et al:High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290-1297, 1997
16) Shipp MA et al:International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas:report of the jury. J Clin Oncol 17:423-429, 1999
17) Ladetto M et al:Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia 15:1941-1949, 2001
18) Armitage JO:The role of mitoxantrone in non-Hodgkin's lymphoma. Oncology (Huntingt) 16:490-502, 507-508;discussion 511-512, 514, 2002
19) Joyce RM et al:Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant. Eur Haematol (Suppl) 64:56-62, 2001
20) 0gura M et al:Pilot phase I/II study of a new salvage chemotherapy (CHASE) for refractory or relapsed malignant lymphomas. Int J Hematol, in press
21) Ogura M et al:Phase I/II study of a new salvage chemotherapy with Rituximab (CHASER therapy) for relapsed advanced follicular lymphoma (FL) and mantle cell lymphoma (MCL). Blood (abstr), 2002
P.73 掲載の参考文献
1) Miller TP et al:Chemotherapy alone compared with chemotherapy plus radiotherapy for lacalized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26, 1998
2) Gianni AM et al:High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290-1297, 1997
3) Coiffier B et al:CHOP chemotherapy plus rituximab compared with CHOP alone in eldery patients with diffuse larege-B-cell lymphoma. N Engl J Med 346:235-242, 2002
4) Plunkett W et al:Comparison of the toxicity and metabolism of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res 40:2349-2355, 1980
5) Tseng WC et al:In vilro biological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol 21:474-477, 1982
6) Huang P et al:Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine. J Biol Chem 265:16617-16625, 1990
7) Huang P et al:Action of 9-β-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism. Mol Pharmacol 39:449-455, 1991
8) Brockman RW et al:Metabolism and chemotherapeutic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L 1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res 40:3610-3615, 1980
9) 白立岩ほか:ヒトCLL及びATL細胞に対するfludarabine phasphateの選択的な細胞増殖阻害効果. Proceedings of the Japanese Cancer Associasion (53rd Annual Meeting):630, 1994
10) Keating MJ:Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin Oncol 17 (Suppl.8):49-62, 1990
11) Carson DA et al:Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L 1210 leukemia in vivo. Proc Natl Acad Sci USA 77:6865-6869, 1980
13) Carson DA et al:Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62:737-743, 1983
15) Yamaguchi M et al:De novo CD5+diffuse large B-cell lymphoma:a clinicopathologic study of 109 Patients. Blood 99:815-821, 2002
16) Weisenburger DD et al:Grading of follicular lymphoma:diagnostic accuracy, reproducibility, and clinical relevance. Mod Pathol 11:142 a, 1998
17) Sarris AH et al:Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone. Semin Oncol 29 (1Supple. 2):48-55, 2002
18) Matolcsy A el al:De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Am J Pathol 147:207-216, 1995
19) Hiddemann W et al:The addition of rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular (FCL) and mantle cell lymphomas (MCL)-results of a prospectiver and ramised comparison of the German Lowgrade Study Group (GLSG) . ASH abstract #3507, 2001
20) Hochster HS et al:Activity of fludarabine in previously treated non-Hodgikin's low-grade lymphoma:results of an Eastern Cooperative Oncology Group Study. J Clin Oncol 10:28-32, 1992
22) Seymour JF el al:Cisplatin, fludarabine, and cytarabine:a novel, pharmacologically designed salvage therapy for patient with refractory, histologically aggressive or mantle cell non-Hodgkin lymphoma. Cancer 94:585-593, 2002
24) Tulpule A et al:Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma. Cancer 83:2370-2376, 1998
25) Di Gaetano N et al:Synergism between fludarabine and riuximab revealed in a follisular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 114:800-809, 2001
26) Rummel MJ et al:In vitro studies with bendamustine:enhanced activity in combination with rituximab. Semin Oncol 29:12-14, 2002
27) Czuczman MS et al:Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 29 (suppl. 2):36-40, 2002
28) Shah P et al:Rituximab and cladribine (2-CdA):in-vivo synergistic activity in B-cell lympho-proliferative disorders (BLPD) expressing the CD20 antigen. Proc Am Soc Clin Oncol 20:228 b, 2001
29) Cohen Y et al:Large-cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine-rituximab-containing regimens:natural history-or therapy-related complication? Eur J Haematol 68:80-83, 2002
30) Tobinai K et al:Prolonged cytopenia and myelodysplastic syndrome (MDS) after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphoma (NHL):result of Japanese phase II study. Proc Am Soc Clin Oncol 20:228 b, 2001
P.77 掲載の参考文献
1) Glick JH et al:An ECOG randomized phase III trial of CHOP versus CHOP plus radiotherapy for intermediate grade early stage non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 14:391, 1995 (abstr)
4) Tirelli U et al:CHOP is the standard regimen in patients≧70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma:Results of a randomized study of the european organization for research and treatment of cancer lymphoma cooperative study group. J Clin Oncol 16:27-34, 1998
5) Kouroukis CT et al:Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non-Hodgkin lymphoma;a systematic review. Ann Intern Med 136:136-143, 2002
7) McLaughlin P et al:Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
8) Igarashi T et al:Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab:a Japanese phase II study. Ann Oncol 13:928-943, 2002
9) Coiffier B et al:Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma:A multicenter phase II study. Blood 92:1927-1932, 1998
10) Vose JM et al:Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma. J Clin Oncol 19:389-397, 2001
13) Czuczman MS:Combination chemotherapy and rituximab. Anti Cancer Drugs 12 (Suppl.2):S15-S19, 2001
P.82 掲載の参考文献
2) Yeo W et al:Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy:a prospective study of 626 patients with identification of risk factors. J Med Virol 62:299-307, 2000
3) Lok AS et al:Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182-188, 1991
4) Omata M et al:Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 324:1699-1704, 1991
5) Yeo W et al:Sequence variations of precore/core and precore promoter regions of hepatitis B virus in patients with or without viral reactivation during cytotoxic chemotherapy. J Viral Hepat 7:448-458, 2000
6) Steinberg JL et al:Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours:precore/core mutations may play an important role. J Med Virol 60:249-255, 2000
7) Lai CL et al:A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339:61-68, 1998
8) Strasser SI et al:Hepatitis viruses and hematopoietic cell transplantation:A guide to patient and donor management. Blood 93:1127-1136, 1999
9) Rizzetto M et al:Response of pre-core mutant chronic hepatitis B infection to lamivudine. J Med Virol 61:398-402, 2000
10) Silvestri F et al:Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol 108:394-396, 2000
11) Yeo W et al:Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 59:263-269, 1999
12) Clark FL et al:Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. J Clin Oncol 9:385-387, 1998
13) Al-Taie OH et al:Prevention of hepatitis B flare-up during chemotherapy using lamivudine:case report and review of the literature. Ann Hematol 78:247-249, 1999
14) Dai MS et al:Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients. Cancer 92:2927-2932, 2001
16) Dervite I et al:Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344:68-69, 2001
17) Senecal D et al:Acute hepatitis B after autologous stem cell transplantation in a man previously infected by hepatitis B virus. Bone Marrow Transplant 24:1243-1244, 1999
18) Skrabs C et al:Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP:a diagnostic and therapeutic challenge. Leukemia 16:1884-1886, 2002
19) Ng HJ et al:Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy:case report. Ann Hematol 80:549-552, 2001
20) Hamaki T et al:Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol 68:292-294, 2001
P.86 掲載の参考文献
1) 飯野四郎ほか:肝炎ウイルスと悪性リンパ腫 日本臨床 58:44, 2000
2) Silvestri F et al:Prevalence of hepatic C virus infection in patients with lymphoproliferative disorders. Blood 87:4296-4301, 1996
3) Mariette X:Lymphomas complicating Sjogren's syndrome and hepatitis C virus infection may share a common pathogenesis:chronic stimulation of rheumatoid factor B cells. Ann Rheum Dis 60:1007-1010, 2001
4) Zuckerman E el al:The effect of antiviral therapy on t (14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood 97:1555-1559, 2001
5) Kitay-Cohen Y et al:Bcl-2 rearrangement in patients with chronic hepatitis C associated with essential mixed cryoglobulinemia type II. Blood 96:2910-2912, 2000
6) De Vita S et al:Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. Blood 90:776-782, 1997
P.87 掲載の参考文献
7) Naschitz JE et al:Primary hepatosplenic lymphoma of the B-cell variety in a patient with hepatitis C liver cirrhosis. Am J Gastroenterol 89:1915-1916, 1994
9) Hausfater P et al:Hepatitis C virus infection and lymphoproliferative disease:prospective study on 1576 patients in France. Am J Hematol 67:168-171, 2001
10) 1999 年「国民衛生の動向」:142, 1999
11) 山崎京子ほか:肝炎患者の病状経過に関連する要因の疫学的検討. 厚生の指標 46:21, 1999
12) Tur-Kaspa R et al:Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 83:1627-1631, 1986
13) Cheng AL:Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma. Blood 87:1202, 1996
14) Markovic S et al:Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. a prospective study in 305 patients. Hepatogastroenterology 46:2925-2930, 1999
15) Zuckerman E et al:Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 83:1224-1230, 1998
16) Page RD et al:Primary hepatic lymphoma:favorable outcome after combination chemotherapy. Cancer 92:2023-2029, 2001
17) Dervite I et al:Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344:68-69, 2001
18) Hermine O et al:Regression of splenic lymphoma with villous lymphocytes after treatment of hepatic C virus infection. N Engl J Med 347:89-94, 2002
19) Patriarca F et al:Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV associated immunocytoma with alpha-interferon treatment. Br J Haematol 112:370-372, 2001
20) Vento S et al:Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 347:92-93, 1996
21) Di Bisceglie AM et al:Ribavirin as therapy for chronic hepatitis C. Ann Intern Med 123:897-903, 1995
22) Poynard T et al:Randomized trial of Interferon α2 b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2 b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432, 1998
P.93 掲載の参考文献
1) Quinn TC:The global HIV/AIDS pandemic. Program and abstracts of the 5th International AIDS Malignancy Conference;April 23-25, 2001, Bethesda, Maryland, Abstract S 23
3) Grulich AE et al:B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS 14:133-140, 2000
4) Cote TR et al:Non-Hodgkin's lymphoma among people with AIDS:Incidence, presentation and public health burden. Int J Cancer 73:645-650, 1997
5) Ledergerber B et al:Risk of HIV related Kaposi:s sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy:Prospective cohort study. BMJ 319:23-24, 1999
6) Mocroft A et al:AIDS across Europe, 1994-1998:The EuroSIDA study. Lancet 356:291-296, 2000
7) International Collaboration on HIV and cancer:Highly active anti-retroviral therapy and incidence of cancer in human immunodeficiency virus infected adults. J Natl Cancer Inst 92:1823-1830, 2000
8) Knwles DM:Molecular pathology of aquired immunodeficiency syndrome-related non-Hodgkin's lymphma. Semin Diag Pathol 14:67-82, 1997
9) Moses AV et al:HIV-1 induction of CD40 on endothelial cells promotes the outgrowth of AIDS-associated B-cell lymphoma. Nat Med 3:1242-1249, 1997
10) Levine AM et al:Low dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma:A prospective multiinstitutional trial. JAMA 266:84-88, 1991
11) Kaplan LD et al:Randomized trial of standard-dose versus low dose mBACOD chemotherapy for HIV-associated non-Hodgkin's lymphoma. N Engl J Med 336:1641-1648, 1997
12) Ratner L et al:Chemotherapy for HIV associated non-Hodgkin's lymphoma in combination with highly active anti-retroviral therapy. J Clin Oncol 19:2171-2178, 2001
14) Sparano JA et al:Infusional cyclophosphamide, doxorubicin and etoposide in HIV associated non-Hodgkin's lymphoma:A review of the Einstein, Aviano, and ECOG experience in 182 patients. Abstracts of the 4th International AIDS Malignancy Conference;May 16-18, 2000;Bethesda, MD. J AIDS 23:A 11, Abstract S 15, 2000
15) Little RF et al:Dose adjusted chemotherapy with suspension of anti-retroviral therapy for HIV associated non-Hodgkin's lymphoma. Abstracts of the 4th International AIDS Malignancy Conference;May 16-18, 2000;Bethesda, Maryland. J AIDS 23:A 11. Abstract S 16, 2000
16) Errante D et al:Second line chemotherapy with CDE in patients with resistant HIV related non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 17:57a, 1998
17) Tirelli U et al:Second line chemotherapy in HIV related non-Hodgkin's lymphoma. Cancer 77:2127-2131, 1996
18) Yuzon R et al:Treatment of relapsed/refractory AIDS related lymphoma with high dose cytarabine/ cisplatine combination regimens. XIII International AIDS Conference, July 9-14, 2000, Durban, South Africa. Abstract MoPpB 085.
19) McLaughlin P et al:Rituximab Chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
21) Coiffier B et al:Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma:A multicenter phase II study. Blood 92:1927-1932, 1998
22) Coiffier B et al:CHOP chemotherapy plus rituximab compared with CHOP alone ill elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
23) Barrett JC et al:Rituximab for the treatment of AIDS-associated non-Hodgkin's lymphoma. J AIDS 21:A40, 1999
24) Barrett JC et al:A pilot study of anti-CD20 MoAb rituximab in AIDS-associated non-Hodgkin's lymphoma. Blood 94 (10, Suppl.1):258 b, 1999
25) Sparano JA et al:Pilot trial of infusional cyclophosphamide, doxorubicin, & etoposide (CDE) plus rituximab in HIV-associated non-Hodgkin's lymphoma (NHL). Blood 94 (10, Suppl.1):268 b, 1999
26) Tirelli U et al:Pilot trial of rituximab and chemo-therapy with infused cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin's lymphoma. Haematologica 85 (7 Suppl):17, 2000
27) Tirelli U et al:Rituximab and infusional cyclophosphamide, doxorubicin, and etoposide (CDE):asafe and highly active regimen in HIV-related non-Hodgkin's lymphoma (NHL). Ann Oncol 13 (Suppl.2):78, 2002
28) Weiss R et al:HIV-related lymphoma. Rituximab concomitant to second-line chemotherapy following tumor progression under CHOP or early relapse. Blood 98:253 b-254 b, 2001
29) De Paoli P et al:Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotherapy. Cancer Immunol Immunother 50:157-162, 2001
P.99 掲載の参考文献
2) Goldenberg DM:The role of radiolabeled anti-bodies in the treatment of non-Hodgkin's lymphoma:the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol 39:195-201, 2001
3) Wahl RL et al:Single center experience with iodine I 131 tositumomab radioimmunotherapy for previously untreated follicular lymphoma (FL). J Nucl Med 41:79 abstr 309, 2000
4) Hansen HJ et al:HAMA interference with murine monoclonal antibody-based immunoassays. J Clin Immunoassay 16:294-299, 1993
5) Rutar FJ et al:Outpatient treatment with 131I-anti-B1 antibody:radiation exposure to family members. J Nucl Med 42:907-915, 2001
8) Wahl RL et al:Iodine-131 anti-B1 antibody for B-cell lymphoma:an update on the Michigan Phase I experience. J Nucl Med 39 (8 Suppl.):21S-27S, 1998
9) Vose JM et al:Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 18:1316-1323, 2000
11) Press OW et al:Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336-340, 1995
13) Press OW et al:A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96:2934-2942, 2000
15) Scheidhauer K et al:Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 29:1276-1282, 2002
16) Wiseman GA et al:Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 27:766-777, 2000
17) Witzig TE et al:Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002
19) TE Witzig et al:Zevalin radioimmunotherapy is safe and well tolerated in patients with relapsed or refractory, B cell non-Hodgkin's lymphoma (NHL). Blood 96:731, 2000
20) Juweid ME et al:Pharmacokinetics, dosimetry, and initial therapeutic results with 131I-and 111In-/90 Y-labeled humanized LL 2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res 5:3292s-3303s, 1999
21) Linden O et al:A Phase I/II trial with Y-90 hLL 2 in recurrent B-Cell lymphomas, preliminary results. Cancer Biother Radiopharm 15:413, 2000
22) Postema EJ el al:Radioimmunotherapy of patients with non-Hodgkin's lymphoma with 186RehLL 2. Cancer Biother Radiopharm 15:407, 2000
23) Linden O et al:131I-labelled anti-CD22 MAb (LL 2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates. Acta Oncol 41:297-303, 2002
25) DeNardo GL et al:Are radiometal-labeled antibodies better than iodine-131-labeled antibodies:comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma. Clin Lymphoma 1:118-126, 2000
26) DeNardo GL et al:Analysis of antiglobulin (HAMA) response in a group of patients with B-lymphocytic malignancies treated with 131I-Lym-1. Int J Biol Markers 10:67-74, 1995
P.106 掲載の参考文献
2) Guglielmi C et al:Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 16:3264-3269, 1998
3) Nademanee A et al:Autologous stem-cell transplantation for poor-risk and relapsed intermediate and high-grade non-Hodgkin's lymphoma. Clinical Lymphoma 1:46-54, 2000
5) Bierman PJ et al:Yttrium 90-labeled antiferritin followed by high-dose chemoradiotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease. J Clin Oncol 11:698-703, 1993
7) Press OW et al:Phase II trial of 1311-B 1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336-340, 1995
9) Behr TM et al:High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C 2 B 8 and autologous stem cell support. Results of a pilot study. Cancer 94 (4 Suppl):1363-1372, 2002
10) Becker W et al:High dose radioimmunotherapy in relapsed B-cell lymphoma with I-131 rituximab. Ann Hematol 80 (Suppl.3:B) 130-131, 2001
11) Press OW et al:A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96, 2934-2942, 2000
12) Gopal AK et al:High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99:3158-3162, 2002
13) Vose JM et al:Radioimmunotherapy with Bexxar combined with high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for refractory non-Hodgkin's lymphoma:synergistic results with no added toxicity. Proc Annu Meet Am Soc Clin Oncol 19:Abstract, 2001
14) Winter JN et al:Phase I trial combining 90Y Zevalin and high-dose BEAM chemotherapy with hematopoietic progenitor cell transplant in relapsed or refractory B-cell NHL. Proc Am Soc Hem:Abstract, 2001
15) Liberti G et al:Comparison of peripheral blood stem-cell and autologous bone marrow transplantation for lymphoma patients:a case-controlled analysis of the EBMT Registry data. Lymphoma Working Party of the EBMT. Ann Oncol 5 (Suppl 2):151-153, 1994
16) Augustine SC et al:Combination therapy for non-Hodgkin's lymphoma:an opportunity for pharmaceutical care in a specialty practice. J Am Pharm Assoc 42:93-100, 2002
17) Hendrix C et al:Establishing a radioimmunotherapy outpatient care clinic for Non-Hodgkin's lymphoma. Semin Oncol Nurs 18 (1 Suppl.1):22-29, 2002
P.111 掲載の参考文献
1) Lennert K et al:Histopathology of non-Hodgkin's lymphomas. ed. by Second, Berlin, Springer Verlag, 1992
2) The non-Hodgkin's lymphoma classification project:A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997
3) Weisenburger DD:Chapter 20:Mantle cell lymphoma. In:Neoplastic Hematopathology. ed. by Knowles DM, Williams & Wilkins, Baltimore, 1992, pp. 617-628
4) The non-Hodgkin lymphoma pathologic classification project:National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
5) Harris NL et al:A revised European-American classification of lymphoid neoplasms:A proposal from the international lymphoma study group. Blood 84:1361-1392, 1994
6) World Health Organization Classification of Tumours:Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. ed. by Jaffe ES, Harris NL, Stein H, Vardiman JW, IARC Press, Lyon, 2001
7) Fisher RI et al:A clinical analysis of two indolent lymphoma entities:mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories):a Southwest Oncology Group study. Blood 85:1075-1082, 1995
8) Harris NL:The revised European-American lymphoma classification. Ann Oncol 7 (Suppl.3):2, 1996
9) Hiddemann W et al:Lymphoma classification the gap between biology and clinical management is closing. Blood 88:4085-4089, 1996
10) Yatabe Y et al:Significance of cyclin D 1 overexpression for the diagnosis of mantle cell lymphoma:a clinicopathologic comparison of cyclin D 1-positive MCL and cyclin D 1-negative MCL-like B-cell lymphoma. Blood 95:2253-2261, 2000
11) Suzuki R et al:Detection of cyclin D l overexpression by real-time reverse-transcriptasse-mediated quanitative polymerase chain reaction for the diagnosis of mantle cell lymphoma. Am J Pathol 159:425-429, 2001
12) Thorselius M et al:Somatic hypermutation and V (H) gene usage in mantle cell lymphoma. Eur J Haematol 68:217-224, 2002
13) Swerdlow SH et al:From centrocytic to mantle cell lymphoma:a clinicopathologic and molecular review of 3 decades. Hum Phatol 33:7-20, 2002
14) Camacho E et al:ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood 99:238-244, 2002
16) Martinez-Climent JA et al:Loss of a novel tumor suppressor gene locus at chromosome 8 p is associated with leukemic mantle cell lymphoma. Blood 98:3479-3482, 2001
17) Bernard M et al:Blastic variant of mantle cell lymphoma:a rare but highly aggressive subtype.Leukemia 15:1785-1791, 2001
18) Anagnostopoulos I et al:Extranodal mantle cell lymphoma mimicking marginal zone cell lymphoma. Histopathol 39:561-565, 2001
P.120 掲載の参考文献
1) Banks P et al:Mantle cell lymphoma:A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 16:637-640, 1992
2) Fisher Rl et al:A clinical analysis of two indolent lymphoma entities:mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories):a Southwest Oncology Group study. Blood 85:1075-1082, 1995
3) Teodorovic I et al:Efficacy of four different regimens in 64 mantle-cell lymphoma cases:clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 13:2819-2826, 1995
4) The Non-Hodgkin's Lymphoma Classification Project:A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997
5) Yatabe Y et al:Significance of cyclin D 1 overexpression for the diagnosis of mantle cell lymphoma:a clinicopathologic comparison of cyclin D 1-positive MCL and cyclin D 1-negative MCL-like B-cell lymphoma. Blood 95:2253-2261, 2000
6) Coiffier B et al:Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma:a multicenter phase II study. Blood 92:1927-1932, 1998
7) Foran JM el al:Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000
10) Howard OM et al:Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma:Molecular Complete Responses Are Not Predictive of Progression-Free Survival. J Clin Oncol 20:1288-1294, 2002
12) Voso MT et al:In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 109:729-735, 2000
13) Magni M et al:Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma:Evidence for a role of both chemotherapy and rituximab infusion. Blood 96:864-869, 2000
14) Witzig TE et al:Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002
15) Press OW et al:Radio-labeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219-1224, 1993
16) Behr TM et al:High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C 2 B 8 and autologous stem cell support. Results of a pilot study. Cancer 94 (4 Suppl):1363-1372, 2002
17) Gopal AK et al:High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99:3158-3162, 2002
18) Slavin S et al:Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763, 1998
21) Khouri IF et al:Allogeneic hematopoietic transplantation for mantle-cell lymphoma:molecular emissions and evidence of graft-versus-malignancy. Ann Oncol 10:1293-1299, 1999
P.126 掲載の参考文献
3) Shipp MA et al:International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas:Report of the Jury. J Clin Oncol 17:423-429, 1999
5) Haioun C et al:Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma:Updated results of the prospective study LNH 87-2. J Clin Oncol 15:1131-1137, 1997
6) Reyers F et al:Failure of first-line inductive high-dose chemotherapy in poor-risk patients with aggressive lymphoma:Updated results of the randomized LNH-93-3 study. Blood 90:594 a, 1997
7) Gianni AM et al:High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290-1297, 1997
8) 張高明ほか:中等度悪性非Hodgkinリンパ腫に対する自己末梢血肝細胞移植併用大量化学療法-臨床前 期第II相試験-. 臨床血液 40:1058-1067, 1999
9) Majoline I et al:Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and Non-Hodgkin's lymphomas:A new matched-pair analysis of the European group for blood and marrow transplantation registry data. J Clin Oncol 15:509-517, 1997
P.127 掲載の参考文献
10) Flohr T et al:Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant 29:769-775, 2002
13) 吉岡聡ほか:非ホジキンリンパ腫に対する同種造血幹細胞移植. 第25回日本造血細胞移植学会総会抄録集 p.143, 2002
14) Carella AM et al:Autografting followed by non-myeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem cell transplantation as treatment of resistant Hodgkin's lymphoma. J Clin Oncol 18:3918-3924, 2002
15) Nagler A et al:Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation. Exp Hematol 28:1096-1104, 2000

[2] Indolent B-cell non-Hodgkin's lymphoma

P.133 掲載の参考文献
1) World Health Organization Classification Tumours:Tumours of Haematopoietic and Lymphoid Tissues. Ed by Jaffe ES, Harris NL, Stein H, Vardiman, IARC Press, 2001
2) Rosenberg SA:The low-grade non-Hodgkin's lymphomas:challenges and opportunities. J Clin Oncol 3:299-310, 1985
3) Horning SJ et al:The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311:1471-1475, 1984
4) Young RC et al:The treatment of indolent lymphomas:watchful waiting v aggressive combined modality treatment. Sem Hematol 25:11-16, 1988
6) Maloney DG et al:IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195, 1997
7) McLaughlin P et al:Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
8) Hainsworth JD et al:Rituximab monoclonal anti-body as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma. Blood 95:3025-3056, 2000
12) Witzig TE et al:Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002
14) Rohatiner AZS et al:Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 12:1177-1184, 1994
15) Bastion Y el al:Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 86:3257-3262, 1995
17) Freedman AS et al:Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94:3325-3333, 1999
18) Magni M et al:Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma:evidence for a role of both chemotherapy and rituximab infusion. Blood 96:864-869, 2000
19) van Besien K et al:Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92:1832-1836, 1998
20) Schimmer AD et al:Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL):results of a provincial strategy. Bone Marrow Transpl 26:859-864, 2000
21) Stein RS et al:High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin. Bone Marrow Transpl 23:227-233, 1999
22) Verdonck LF et al:Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 90:4201-4205, 1997
23) Khouri IF et al:Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma:low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98:3595-3599, 2001
P.139 掲載の参考文献
1) Kondo E et al:Assessment of prognostic factors in follicular lymphoma patients. Int J Hematol 73:363-368, 2001
2) Tobinai K et al:Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal anti-body (IDEC-C 2 B 8, rituximab) in relapsed B-cell lymphoma. Ann Oncol 9:527-534, 1998
3) lgarashi T et al:Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab:a Japanese phase II study. Ann Oncol 13:928-943, 2002
4) Igarashi T et al:Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int J Hematol 73:213-221, 2001
P.140 掲載の参考文献
5) 菊池我子ほか:再発 B-NHLに対する抗CD20抗体rituximab併用化学療法CHASERの臨床第1/2 相試験.第64回日本血液学会総会 (演題N-WS 7-7)
6) Colombat P et al:Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden:clinical and molecular evaluation. Blood 97:101-106, 2001
7) Winkler U et al:Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C 2 B 8). Blood 94:2217, 1999
P.146 掲載の参考文献
2) Maloney DG et al:IDEC-C 2 B 8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195, 1997
4) Hainsworth JD et al:Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95:3052-3056, 2000
5) Colombat P et al:Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden:clinical and molecular evaluation. Blood 97:101-106, 2001
8) Jaeger G et al:Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma:a phase II study. Eur J Haematol 69:21-26, 2002
9) Whelan JS et al:Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer 64:120-123, 1991
10) Foran JM et al:Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with"low-grade"non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. J Clin Oncol 17:1574-1579, 1999
11) Di Gaetano N et al:Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 114:800-809, 2001
12) McLaughlin P et al:Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 27 (6 Suppl.12):37-41, 2000
13) Hunault-Berger M et al:Intensive therapies ill follicular non-Hodgkin lymphomas. Blood 100:1141-1152, 2002
14) Gribben JG et al:Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Eng J Med 325:1525-1533, 1991
15) Freedman AS et al:Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94:3325-3333, 1999
16) Lazzarino M et al:A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 116:229-235, 2002
17) Magni M et al:Successful in vivo purging of CD34 containing peripheral blood harvests in mantle cell and indolent lymphoma:evidence for a role of both chemotherapy and rituximab infusion. Blood 96:864-869, 2000
P.152 掲載の参考文献
1) Knox SJ et al:Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2:457-470, 1996
3) Wiseman GA et al:Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia:a phase II multicenter trial. Blood 99:4336-4342, 2002
4) Kaminski MS et al:Radioimmunotherapy of B-cell lymphoma with [1311] anti-B1 (anti-CD20) antibody. N Engl J Med 329:459-465, 1993
6) Kaminski MS et al:Radioimmunotherapy with iodine (131) I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma:updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259-1266, 2000
8) Witzig TE et al:Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002
P.158 掲載の参考文献
1) Brockman RW et al:Metabolism and chemotherapeutic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L 1210 and its evidence for its phosphorylation by deoxycytidine kinase. Cancer Res 40:3610-3615, 1977
2) Solal-Celigny P et al:Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma:A multicenter study by the groupe d'Etude des lymphomas de l'adulte. J Clin Oncol 14:514-519, 1996
3) Hochster HS et al:Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma:results and long-term follow-up-a report from the Eastern Cooperative Oncology Group. J Clin Oncol 18:987-994, 2000
4) Flinn IW et al:Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 96:71-75, 2000
5) Hochster HS et al:Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma:results of an Eastern Cooperative Oncology Group study. J Clin Oncol 10:28-32, 1992
P.159 掲載の参考文献
7) Zinzani PL et al:Fludarabine an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol 4:575-578, 1993
8) Mclaughin P et al:Fludarabine, mitoxantrone, and dexamethasone:an effective new regimen for indolent lymphoma. J Clin Oncol 14:1262-1268, 1996
9) Seto S et al:Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to non dividing human lymphocytes. J Clin Invest 75:377-383, 1985
10) Beutler E:Cladribine (2-chlorodeoxyadenosine). Lancet 340:952-956, 1992
11) Saven A et al:2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood 86:1710-1716, 1995
14) Van Den Neste E et al:Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Leukemia 14:1136-1142, 2000
15) Robak T et al:Cladribine in combination with mitoxantrone and cyclophosphamide (CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies. Eur J Haematol 66:188-194, 2001
16) Rummel M et al:Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma. Eur J Cancer 38:1739-1746, 2002
17) Tondini C el al:Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma:a phase II randomized study. Ann Oncol 11:231-233, 2000
19) Czuczman M et al:Progression free survival (PFS) after six years (Median) follow-up of the first clinical trial of Rituximab/CHOP chemoimmunotherapy. The 43rd Annual Meeting of the American Society of Hematology (Abstruct) #2519, 2001
20) 小林幸夫ほか:再発・再燃した低悪性度非ホジキンリンパ腫に対するクラドリビンの臨床第II相試験 (II):抗腫瘍効果の検討第63回日本血液学会総会 (abstract) 347, 2001
21) DI Gaetano N et al:Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 114:800-809, 2001
22) Chow KU et al:Anti-CD20 antibody (IDEC-C 2 B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro:role of cytokines, complement, and caspases. Haematologica 87:33-43, 2002
23) Shah PK et al:2-chlorodeoxyadenosine (2-CDA) with weekly retuximab and granulocyte-macrophage colony stimulating factor (GM-CSF):a highly effective regimen for advanced B-cell lymphoproliferative disorders (BLPD). The 43rd Annual Meeting of the American Society Hematology (Abstruct) #4726, 2001
24) Czuczman MS et al:Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 29:36-40, 2002
25) Hiddemann W et al:The addition of retuximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed of refractory follicular (FCL) and mantle cell lymphomas (MCL)-results of prospective randomized comparison of the german low grade study group (GLSG). The 43rd Annual Meeting of the American Society Hematology (Abstruct) #3507, 2001
26) Giralt S et al:Melphalan and purine-analog-containing preparative regiments:reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97:631-637, 2001
27) 峯石真:クラドリビンまたはフルダラビンおよびブスルファンを用いたミニ移植. 血液・腫瘍科 43:352-355, 2001
P.160 掲載の参考文献
28) Foran JM et al:Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" Non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. J Clin Oncol 17:1574-1579, 1999
29) Tobinai K et al:Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Jpn J Clin Oncol 27:146-153, 1997
P.166 掲載の参考文献
1) Freedman AS et al:Long-term follow-up of autologous bone marrow transplantation) in patients with relapsed follicular lymphoma. Blood 94:3325-3333, 1999
2) Schouten HC et al:The CUP trial:a randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 11 (Suppl.1):91-94, 2000
3) Williams CD et al:High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma:a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 19:727-735, 2001
4) Horning SJ et al:High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission results of a phase II clinical trial. Blood 97:404-409, 2001
7) Voso MT et al:Autografting with CD34+peripheral blood stem cells:retained engraftment capability and reduced tumour cell content. Br J Haematol 104:382-391, 1999
8) Magni M et al:Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma:evidence for a role of both chemotherapy and rituximab infusion. Blood 96:864-869, 2000
9) Press OW et al:A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96:2934-2942, 2000
11) van Besien K et al:Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92:1832-1836, 1998
13) Khouri IF et al:Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma:low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98:3595-3599, 2001
15) Tanimoto TE et al:High complete resonse rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma. Bone Marrow transplantation, in press.
16) Robinson S et al:Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced intensity allogeneic progenitor cell transplantation:an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100:4310-4316, 2002
17) Hunault-Berger M et al:Intensive therapies in follicular non-Hodgkin lymphomas. Blood 100:1141-1152, 2002
20) Kottaridis PD el al:In vivo CAMPATH-1 H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96:2419-2425, 2000
P.174 掲載の参考文献
1) Harris NL et al:A revised European-American classification of lymphoid neoplasms:a proposal from the International Lymphoma Study Group[see comments]. Blood 84:1361-1392, 1994
2) Mac Manus MP et al:Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14:1282-1290, 1996
5) Longo DL et al:Prolonged initial remission in patients with nodular mixed lymphoma. Ann Intern Med 100:651-656, 1984
6) Einat M et al:Close link between reduction of c-myc expression by interferon and, G O/G 1 arrest. Nature 313:597-600, 1985
8) Gutterman JU:Cytokine therapeutics:lessons from interferon alpha. Proc Natl Acad Sci USA 91:1198-1205, 1994
9) Hattori T et al:Interferon-induced differentiation of U 937 cells. Comparison with other agents that promote differentiation of human myeloid or monocyte like cell lines. J Clin Invest 72:237-244, 1983
10) Borden EC:Interferons:pleiotropic cellular modulators. Clin Immunol Immunopathol 62 (1 Pt 2):S18-24, 1992
11) Wadler S et al:Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies:a review. Cancer. Res 50:3473-3486, 1990
12) Merigan TC el al:Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N Engl J Med 299:1449-1453, 1978
13) Horning SJ et al:Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the American Cancer Society trial. Cancer 56:1305-1310, 1985
14) Wagstaff J et al:A phase II study of human rDNA alpha-2 interferon in patients with low grade non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 18:54-58, 1986
15) VanderMolen LA et al:Low-versus high-dose interferon alfa-2 a in relapsed indolent non-Hodgkin's lymphoma. J Natl Cancer Inst 82:235-238, 1990
16) Chisesi T et al:Randomized study of chlorambucil (CB) compared to interferon (alfa-2 b) combined with CB in low-grade non-Hodgkin's lymphoma:an interim report of a randomized study. Non-Hodgkin's Lymphoma Cooperative Study Group. Eur J Cancer 27 (Suppl.4):S31-33, 1991
17) Price CG et al:Interferon-alpha 2 b in the treatment of follicular lymphoma:preliminary results of a trial in progress. Ann Oncol 2 (Suppl.2):141-145, 1991
19) Solal-Celigny P et al:Recombinant interferon alfa-2 b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med 329:1608-1614, 1993
20) Solal-Celigny P et al:Doxorubicin-containing regimen with or without interferon alfa-2 b for advanced follicular lymphomas:final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial[see comments]. J Clin Oncol 16:2332-2338, 1998
21) Andersen JW et al:Interferon alfa plus chemotherapy for non-Hodgkin's lymphoma:five-year follow-up [letter]. N Eng J Med 329:1821-1822, 1993
22) Hagenbeek A et al:Maintenance of remission with human recombinant interferon alfa-2 a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 16:41-47, 1998
23) Aviles A et al:Interferon alpha 2 b as maintenance therapy in low-grade malignant lymphoma improves duration of remission and survival. Leuk Lymph 20:495-499, 1996
24) Unterhalt M et al:Long-term interferon alpha maintenance prolongs remission duration in advanced low-grade lymphomas and is related to the efficasy of initial cytoreductive chemotherapy (abstract). Blood 88 (10 suppl 1):453 a, 1996
25) Anderson KC et al:Expression of human B cell-associated antigens on leukemias and lymphomas:A model of human B cell differentiation. Blood 63:1424-1433, 1984
26) Reff ME et al:Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445, 1994
27) Shan D et al:Signaling events involved in anti-CD20-induced apoptosis of malignant human B ells. Cancer Immunol Immunother 48:673-683, 2000
29) McLaughlin P et al:rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
30) Coiffier B et al:rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma:A multicenter phase II study. Blood 92:1927-1932, 1998
31) Foran JM et al:European phase II study of rituximab ( chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000
32) Foran JM et al:Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody):Analysis of factors associated with response. Ann Oncol 11 (suppl. 1):117-121, 2000
33) Steve Alas et al:Rituximab Inactivates Signal Transducer and Activation of Transcription 3 (STAT 3) Activity in B-Non-Hodgkin's Lymphoma through Inhibition of the Interleukin 10 Autocrine/Paracrine Loop and Results in Down-Regulation of Bcl-2 and Sensitization to Cytotoxic Drugs. Cancer Research 61:5137-5144, 2001
34) Sivaraman S et al:Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia. Cytokines Cell Mol Ther 6:81-87, 2000
35) Gidlund M et al:Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature 273:759-761, 1978
36) Herberman RB et al:Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity. Nature 227:221-223, 1979
37) Herberman RB:Effect of α-interferon on immune function. Semin Oncol 24 (Suppl 9):S9-78-S 9-80, 1997
38) Davis TA et al:Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2 a. Clin Cancer Res 6:2644-2652, 2000
39) Sacchi S et al:Clinical activity and safety of combination immunotherapy with IFN-alpha 2 a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 86:951-958, 2001
40) Kimby E el al:Rituximab (MabThera) as single agent and in combination with interferon-a 2 a as treatment of untreated and first relapse follicular or other low grade lymphomas. A randomized phase II study M 39035. Blood 96 (suppl. 1):577 a, 2000 (abstr)
41) Sivaraman S et al:Effects of recombinant human granulocyte colony-stimulating factor administration on neutrophil phenotype and functions. Haematologica 82:606-616, 1997
42) Stockmeyer B et al:Mechanisms of G-CSF-or GM-CSF stimulated tumor cell killing by Fc receptor-directed bispecific antibodies. J Immunol Methods 248:103-111, 2001
43) van der Kolk LE et al:Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF:Final report on safety and efficacy. Blood 96 (suppl. 1):512 a, 2000 (abstr)
44) Allen IE et al:Meta-analysis to assess the efficacy of interferon-α in patients with follicular non-Hodgkin's lymphoma. J Immunol 24:58-65, 2001
P.180 掲載の参考文献
1) Spencer J et al:Human marginal-zone B cells. Immunol Today 19:421-426, 1998
2) Harris NL et al:European-American classification of lymphoid neoplasm:a proposal from the international Study Group. Blood 84:1361-1392, 1994
3) Isaacson 1:et al:Malignant lymphoma of mucosa-associated lymphoid tissue-A distinctive type of B-cell lymphoma. Cancer 52:1410-1416, 1993
4) Motegi M et al:API2-MALTl chimeric transcripts involved in mucosa-associated lymphoid tissue type lymphoma predict heterogeneous products. Am J Pathol 156:807-812, 2000
5) Wotherspoon AC et al:Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter Pylori. Lancet 342:575-577, 1993
6) Nakamura T et al:The t (11;18) (q21;q21) translocation in H. Pylori-negative low-grade gastric MALT lymphoma. Am J Gastroenterol 11:3314-3315, 2000
7) Savio A et al:Diagnosis and posttreatment follow-up of Helicobacter pylori-positive gastric lymphoma of mucosa-associated lymphoid tissue:histology, polymerase chain reaction, or both? Blood 87:1255-1260, 1996
8) Roggero E et al:Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 122:767-769, 1995
9) Bayerdorffer E et al:Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 345:1591-1594, 1995
P.181 掲載の参考文献
11) 中村常哉ほか:Helicobacter pylori除菌療法をめぐる controversy Helicobacter pylori 陰性例に対する除菌療法の意義.胃と腸 33:493-495, 1998
12) Yokoi T et al:Primary low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma with polypoid appearance. Polypoid gastric MALT lymphoma:A clinicopathologic study of eight cases. Pathol Int 49:702-709, 1999
14) 鈴木達彦ほか:胃MALTリンパ腫のHelicobacter pylori除菌後の経過内視鏡像・病理組織像と治療後の変化. 胃と腸 34:1367-1379, 1999
16) Akaza K et al:Clinicopathologic study of primary gastric lymphoma of B-cell phenotype with special reference to low-grade B-cell lymphoma of mucosa-associated lymphoid tissue among the Japanese. Pathol Int 45:832-845, 1995
18) 0tt G et al:The t (11;18) (q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type. Cancer Res 57:3944-3948, 1997
19) 中村常哉ほか:胃MALTリンパ腫とHelicobacter pylori感染との関連に関する研究. 日本消化器内視鏡 学会雑誌 38:1488-1499, 1996
20) Akagi T et al:Anovel gene, MALT 1 at 18 q 21, is involved in t (11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 18:5785-5794, 1999
21) Dierlamm J et al:The apoptosis inhibitor gene API 2 and a novel 18 q gene, MLT, are recurrently rearranged in the t (11;18) (q21;q21) p6 associated with mucosa-associated lymphoid tissue lymphomas. Blood 93:3601-3609, 1999
22) Liu H et al:Resistance of t (11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 357:39-40, 2001
23) Schmid U et al:Development of malignant lymphoma in myoepithelial sialadenitis (Sjogren's syndrome). Virchows Arch A Pathol Anat Histol 395:11-43, 1982
P.184 掲載の参考文献
1) Isaacson P et al:Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 52:1410-1416, 1983
P.185 掲載の参考文献
2) Wotherspoon AC et al:Helicobacter pylori associated gastritis and primary B-cell gastric lymphoma. Lancet 338:1175-1176, 1991
4) Wotherspoon AC et al:Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342:575-577, 1993
5) Stolte M et al:Healing gastric MALT lymphomas by eradicating H pylori? Lancet 342:568, 1993
6) Neubauer A et al:Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 89:1350-1355, 1997
7) 日本ヘリコバクター学会ガイドライン. 日本ヘリコバクター学会誌 2:2, 2000
8) Bayerdorffer E el al:Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection Malt. Lancet 345:1591-1594, 1995
9) Morgner A et al:Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol 19:2041-2048, 2001
10) Chen LT et al:Prospective study of Helicobacter pylori eradication therapy in stages I (E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol 19:4245-4251, 2001
11) Nakamura S et al:Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. Gut 48:454-460, 2001
12) Ruskone-Fourmestraux A et al:Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut 48:297-303, 2001
13) Yamashita H et al:When can complete regression of low-grade gastric lymphoma of mucosa-associated lymphoid tissue be predicted after helicobacter pylori eradication? Histopathology 37:131-140, 2000
15) Liu H et al:Resistance of t (11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 357:39-40, 2001
16) Liu H et al:T (11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 122:1286-1294, 2002
20) 紀藤 毅ほか:胃MALTリンパ腫の治療法選択と予後. 胃と腸 31:93-98, 1996
21) Cogliatti SB el al:Primary B-cell gastric lymphoma:a clinicopathological study of 145 patients. Gastroenterology 101:1159-1170, 1991

[3] Highly aggressive B-cell non-Hodgkin's lymphoma

P.196 掲載の参考文献
1) The non-Hodgkin's lymphoma pathologic classification project:National cancer institute sponsored study of classification of non-Hodgkin's lymphomas. Summary and description of a Working Formulation for Clinical Usage. Cancer 49:2112-2135, 1982
2) Harris NC et al:A revised European-American classification of lymphoid neoplasms:A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
3) Hiddemann W et al:Lymphoma classification:The gap between biology and clinical management is closing. Blood 88:4085-4089, 1996
4) World Health Organization classification of tumors. Pathology and Genetics of tumors of haematopoietic and lymphoid tissues. ed. by Jaffe EF, Harris NH, Stein H et al, IARCPress, Lyon, 2001
5) Hutchison RE et al:Diffuse small noncleaved cell lymphoma in children, Burkitt's versus non-Burkitt's types:Results from the Pediatric Oncology Group and St. Jude Children's Research Hospital. Cancer 64:23-28, 1989
6) Bernstein JI et al:Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). J Clin Oncol 4:847-858, 1986
9) Haddy TB et al:CNS involvement in small non-cleaved-cell lymphoma:Is CNS disease per se a Poor prognostic sign?. J Clin Oncol 9:1973-1982, 1991
10) Mashal RD et al:Small non-cleaved cell lymphoma in adults. Am J Hematol 38:40-47, 1991
12) Bishop PC et al:Burkitt's lymphoma:Molecular pathogenesis and treatment. Cancer invest 18:574-583, 2000
14) Anderson JR el al:Long-term follow-up of patients treated with COMP or LSA 2-L 2 therapy for childhood non-Hodgkin's lymphoma:A report of CCG-551 from the Children Cancer Group. J Clin Oncol 11:1024-1032, 1993
15) Magrath IT et al:An effective therapy both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 63:1102-1111, 1984
16) Herbrecht R et al:Small noncleaved cell lymphomas:Clinical study of 39 cases treated with LNH-84 regimen. Proc Am Sos Clin Oncol 8:615, 1989
18) Magrath I et al:Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14925-934, 1996
19) Reiter A et al:Non-Hodgkin's lymphomas of childhood and adolescence:results of a treatment stratified for biologic subtypes and stage. A report of the Belrin-Frankfurt-Munster Group. J Clin Oncol 13:359-372, 1995
20) Patte C et al:High survival rate in advanced-stage B-cell lymphomas and leukemia's without CNS involvement with short intensive chemotherapy:result from the French Pediatric Oncology Society of randomized trial of 216 children. J Clin Oncol 9:123-132, 1991
23) Kemeny MM et al:The role of surgery in the management of American Burkitt's lymphoma and its treatment. Ann Surg 196:82-86, 1982
24) Stovroff MC et al:The role of surgery in American Burkitt's lymphoma in children. J Pediatr Surg 26:1235-1238, 1991
26) Sweetenham JW el al:Adult Burkitt's and Burkitt's-like non-Hodgkin's lymphoma-Outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse:Results from the European group for blood and marrow transplantation. J Clin Oncol 14:2465-2472, 1996
P.202 掲載の参考文献
1) Diebold et al:Burkitt lymphoma. Pathology & Genitics Tumor of Haematopoietic and Lymophoi Tissues. ed. by Jaffe et al World health organization classification of tumours, 2001, pp 181-184
2) Soussain C et al:Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 85:664-674, 1995
4) Harris E et al:Burkitt's lymphoma:single-centre experience with modified BFM protocol. Clin Lab Haematol 24:111-114, 2002
5) Haddy TB et al:CNS involvement in small non-cleaved-cell lymphoma:Is CNS disease per se a poor prognostic sign? J Clin Oncol 9:1973-1982, 1991
6) Morrison VA et al:Prognositic factors for therapeutic outcome of diffuse small non-cleaved cell lyrnphoma in adults. Am J Hematol 46:295-303, 1994
7) Kaiser U et al:Non-Hodgkin's lymohoma protocols in the treatment of patients with Burkitt's lymphoma and lymphoblastic lymphoma:A report on 58 patients. Leuk lymphoma 36:101-108, 1999
8) 日本造血細胞移植学会:造血幹細胞移植の適応ガイドライン 2000年, pp 48-57
9) Nademanee A et al:Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate and high-grade lymphoma:international index high and high-intermediate risk group. Blood 90:3844-3852, 1997
10) Sweetenham JW el al:Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma-outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse:results from the European Group for Blood and Marrow Transplantation. J Clin Oncol 14:2465-2472, 1996
P.203 掲載の参考文献
11) Brunning et al:Precursor B lymphoblastic leukemia/lymphoblastic lymphoma (precursor B-cell acute lymphoblastic leukemia) . Pathology & Genitics Tumor of Haematopoietic and Lymophoi Tissues. ed by Jaffe et al, World health organization classification of tumours, 2001, pp 111-114
12) Lin P et al:Precursor B-cell lymphoblastic lymphoma:A predominatly extranodal tumor with low propensity for leukemic involvement. Am Surg Pathol 24:1480-1490, 2000
13) Soslow RA et al:B-Lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology. Cancer 85:2648-2654, 1999
14) Sweetenham JW et al:High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma:results of a randamized trial of the European group for blood and marrow transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 19:2927-2936, 2001
17) Thomas DA et al:Lymphoblastic lymphoma. Advances in the treatment of adult acute lymphocytic leukemia part II. Hematol Oncol Clin North Am 15:51-95, 2001
P.208 掲載の参考文献
1) Longo DL et al:Superiority of ProMACECytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma:results of a prospective randomized trial. J Clin Oncol 9:25-38, 1991
3) Miller TP et al:Unfavorable histologies of Non-Hodgkin's lymphoma treated with ProMACE-CytaBOM:a groupwide Southwest Oncology Group study. J Clin Oncol 8:1951-1958, 1990
5) Klimo P et al:MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102:596-602, 1985
7) Fisher RI et al:A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate-or high-grade non-Hodgkin's lymphoma:results of SWOG-8516, the National High-Priority Lymphoma Study. Ann Oncol 5 (Suppl.2):91-95, 1994
P.215 掲載の参考文献
1) Canellos GP et al:The Lymphoma. WB Saunders, 1998
3) Phillip T et al:Effective multiagent chemotherapy in children with advanced B cell lymphoma:Who remains the high-risk patient? Br J Haematol 65:159-164, 1987
4) Schwenn M et al:HiC-COM:A 2-month intensive chemotherapy protocol for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia. J Clin Oncol 9:133-138, 1991
5) Reiter A et al:Favorable outcome of B-cell acute lymphoblastic leukemia in childhood:a report of the three consecutive studies of the Berlin-Frankfurt-Munster Group. Blood 80:2471-2478, 1992
6) Atra A et al:Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL):results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol. Br J Cancer 82:1396-1402, 2000
7) Lopez TM et al:Small noncleaved cell lymphoma in adults:Superior results for stage I-III. J Clin Oncol 8:615-622, 1990
9) Longo DL et al:Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults:A high-grade lymphoma responsive to ProMACE-based combination chemotherapy. J Clin Oncol 12:2153-2159, 1994
10) Magrath IT et al:An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 63:1102-1111, 1984
11) Magrath IT et al:Adults and children with small non-leaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925-934, 1996
12) Adde M et al:Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Semin Oncol 25:33-39, 1998
14) Gianni AM et al:High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290-1297, 1997
15) Fisher RI et al:Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Eng J Med 328:1002-1006, 1993

[4] B細胞非ホジキンリンパ腫に対する新たな分子標的治療

P.222 掲載の参考文献
1) Lundin J et al:Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1 H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100:768-773, 2002
3) Lundin J et al:CAMPATH-1 H monoclonal anti-body in therapy for previously treated low-grade non-Hodgkin's lymphomas:a phase II multicenter study. European Study Group of CAMPATH-1 H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 16:3257-3263, 1998
5) Link BK et al:Phase I study of Hu 1 D 10 monoclonal antibody in patients with B-cell lymphoma. Proc Am Soc Clin Oncol 20:244 a, 2001
6) Wang H et al:Analysis of 1 D 10 antigen expression in human malignant tissues:Implications for clinical use of Hu 1 D 10. Proc Am Soc Clin Oncol 20:296a, 2001
8) Linden O et al:131I-labelled anti-CD22 MAb (LL 2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates. Acta Oncol 41:297-303, 2002
9) Hajjar G et al:Interim Results of a Phase I/II Radioimmunotherapy Trial in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) Patients Given 90Y-Labeled Anti-CD22 Humanized Monoclonal Antibody, Epratuzumab. Blood 97:2560 a, 2001
12) DeNardo GL et al:67Cu-versus 131I-labeled Lym-1 antibody:comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin Cancer Res 5:533-541, 1999
13) Grossbard ML et al:Serotherapy of B-cell neoplasms with anti-B 4-blocked ricin:a phase I trial of daily bolus infusion. Blood 79:576-585, 1992
14) Multani PS et al:Phase II clinical trial of bolus infusion anti-B 4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res 4:2599-2604, 1998
15) Grossbard ML et al:A Phase II study of adjuvant therapy with anti-B4 blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res 5:2392-2398, 1999
16) Stone MJ et al:A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD 37-dgA, in patients with B-cell lymphoma. Blood 88:1188-1197, 1996
17) Amlot PL et al:A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82:2624-2633, 1993
18) Sausville EA:Continuous infusion of the anti-CD22 immunotoxin IgG-RFB 4-SMPT-dgA in patients with B-cell lymphoma:a phase I study. Blood 85:3457-3465, 1995
19) Messmann RA:A phase I study of combination therapy with immunotoxins IgG-HD 37-deglycosylated ricin A chain (dgA) and IgG-RFB 4-dgA (Combotox) in patients with refractory CD19 (+), CD22 (+) Bcell lymphoma. Clin Cancer Res 6:1302-1313, 2000
21) Hartmann F et al:Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 89:2042-2047, 1997
P.230 掲載の参考文献
1) Adams J et al:Proteasome Inhibitors:A Novel Class of Potent and Effective Antitumor Agents. Cancer Res 59:2615-2622, 1999
3) Cusack JC Jr et al:Enhanced Chemosensitivity to CPT-11 with Proteasome Inhibitor PS-341:Implications for Systemic Nuclear Factor-B Inhibition. Cancer Res 61:3535-3540, 2001
4) Tan C et al:Proteasome Inhibitor PS-341, a Potential Therapeutic Agent for Adult T-Cell Leukemia. Cancer Res 62:1083-1086, 2002
5) Richardson PG et al:Phase II study of the proteasome inhibitor PS-341 in multiple myeloma (MM) patients (pts) with relapsed/refractory disease. Proc Am Soc Oncol 21:11s, 2002
6) Cotter FE:Antisense therapy of hematologic malignancies. Semin Hematol 36 (suppl.6):9-14, 1999
11) Wooldridge JE et al:Immunostimulatory oligodeoxynucleotides containing CpG motif enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 89:2994-2998, 1997
12) Link BK et al:Phase I study to assess safety and activity of oligodeoxynucleotide CpG 7909 (PromuneTM) in patients with previously treated non-Hodgkin's lymphoma. Blood 98:608 a, 2001 (abstract 2550)
14) Zhang C et al:Induction of Apoptosis by Bexarotene in Cutaneous T-Cell Lymphoma Cells-Relevance to Mechanism of Therapeutic Action. Clin Cancer Res 8:1234-1240, 2002
16) Byrd JC et al:Depsipeptide (FR 901228):A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 94:1401-1408, 1999
17) Sandor V et al:Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR 901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8:718-728, 2002
18) Piekarz RL et al:Inhibitor of histone deacetylation, depsipeptide (FR 901228), in the treatment of peripheral and cutaneous T-cell lymphoma:a case report. Blood 98:2865-2868, 2001
19) Piekarz R et al:Potential value of the histone deacetylase inhibitor depsipeptide (FR 901228) in the treatment of peripheral and cutaneous T-cell lymphoma. Clin Cancer Res 7:3726 a, 2001
20) Senderowicz AM:Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia 15:1-9, 2001
21) Kaur G et al:Growth inhibition with reversible cell cycle arrest of carcinoma cells by Flavone L 86-8275. J Natl Cancer Inst 84:1736-1740, 1992
22) Arguello F et al:Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91:2482-2490, 1998
25) Akinaga S et al:Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 51:4888-4892, 1991
26) Akiyama T et al:G 1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK 2 proteins as well as induction of CDK inhibitor p 21/Cip 1/WAF 1/Sdi 1 in p 53-mutated human epidermoid carcinoma A 431 cells. Cancer Res 57:1495-1501, 1997
27) Sausville EA et al:Phase I trial of 72-hour continuous infusion UCN-Ol in patients with refractory neoplasms. J Clin Oncol 19:2319-2333, 2001
28) Wilson WH et al:Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine:presentation of a novel therapeutic paradigm. Clin Cancer Res 6:415-421, 2000

[5] 遺伝子診断 ~腫瘍の発症機序の研究から実際の治療への適用~

P.244 掲載の参考文献
1) Kuppers R et al:Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 20:5580-5594, 2001
2) 谷脇雅史ほか:診断のための必要な知識:染色体分析とFISH法. 特集;悪性リンパ腫. 内科 90:101-105, 2002
3) Jaffe ES et al:In pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours, IARC Press, Lyon, 2001, pp. 162-170
4) Takashima T et al:Detection of 14 q 32. 33 translocation and t (11;14) in interphase nuclei of chronic B-cell leukemia/lymphomas by in situhybridization. Int J Cancer 72:31-38, 1997
5) Tamura A et al:Delineation of the breakpoint at 18q21. 1 in a cell line (Karpas 1106) derived from mediastinal B-cell lymphoma by fluorescence in situ hybridization with multiple YAC clones. Int J Cancer 78:100-105, 1998
6) Akagi T et al:A novel gene, MALTI at 18 q 21, is involved ill t (11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 18:5785-5794, 1999
7) Levine EG et al:Four new recurring translocations in non-Hodgkin lymphoma. Blood 74:1796-1800, 1989
8) Nakamura T et al:Clinicopathologic Comparison between the API 2-MALT 1 Chimeric Transcript-positive and-negative Gastric Low-grade B-Cell Lymphoma of Mucosa-associated Lymphoid Tissue Type. Jpn J Cancer Res 93:677-684, 2002
P.245 掲載の参考文献
10) Barth TF et al:Characteristic pattern of chromosomal gains and losses in primary large Bcell lymphomas of the gastrointestinal tract. Blood 91:4321-4330, 1998
11) Liu H et al:t (11;18) (q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL 10. Blood 98:1182-1187, 2001
12) Streubel B et al:T (14;18) (q32;q21) involving IGH and MALT l is a frequent chromosomal aberration in MALT lymphoma. Blood[epub ahead of print], 2002
13) Lymphoma Study Group of Japanese Pathologists:The world health organization classification of malignant lymphomas in Japan:Incidence of recently recognized entities. Pathology International 50:696-702, 2000
14) Barrans SL et al:Rearrangement of the BCL 6 locus at 3 q 27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol 117:322-332, 2002
16) Nanjangud G et al:Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma. Blood 99:2554-2561, 2002
17) Ueda C et al:The gene for interleukin-21 receptor is the partner of BCL 6 in t (3;16) (q27;p11), which is recurrently observed in diffuse large B-cell lymphoma. Oncogene 21:368-376, 2002
18) Akasaka T et al:Nonimmunoglobulin (non-Ig)/BCL 6 gene fusion in diffuse large B-cell lymphoma results in worse prognosis than Ig/BCL 6. Blood 96:2907-2909, 2000
19) Shiota M et al:Anaplastic large cell lymphomas expressing the novel chimeric protein p 80 NPM/ALK:a distinct clinicopathologic entity. Blood 86:1954-1960, 1995
20) Kamada N et al:Chromosome abnormalities in adult T-cell leukemia/lymphoma:a karyotype review committee report. Cancer Res 52:1481-1493, 1992
22) Thangavelu M et al:Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sezary syndrome. Blood 89:3371-3377, 1997
23) Ichikawa A et al:Mutations of the p 53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529-534, 1997
24) 赤野由美子:Bリンパ腫210例のFISHとSKYによる染色体遺伝子診断. 臨床血液 43:413-417, 2002
25) Fukuhara S et al:Significance of extra 18 q-chromosome in Japanese t (14;18)-positive lymphoma. Blood 71:1748-1751, 1998
26) Ott G et al:Blastoid variants of mantle cell lymphoma:frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 89:1421-1429, 1997
27) Nomura K et al:Differentiation of follicular from mucosa-associated lymphoid tissue lymphoma by detection of t (14;18) on single cell preparations and paraffin-embedded sections. Genes Chromosomes Cancer 33:213-216, 2002
28) 中村栄男ほか:B細胞悪性リンパ腫の病理と分子病態. 内科 90:394-402, 2002

最近チェックした商品履歴

Loading...